Как я тебя люблю...

AHSGGJAHFV GUNNNN

I 💙 mrsa

Zero to Hero - Temporada 3

🏁Objetivos:

Liga 3: Evitar despromoção✅

Taça de Portugal: Ser competitivo✅

Durante a época ainda verificou-se algumas alterações no plantel

🟢Entradas

Rui Monteiro⬅️Porto B (Liga 3)

Tiago Ferreira⬅️Sporting B (Liga 3)

⚜️100 jogos como treinador

67🟢

15🟠

18🔴

Primeira Fase

🥇Melhor Ataque (44 golos)

Uma primeira fase que me fez acreditar que era possível a subida, apesar de inicialmente a preocupação era de não descer

Fase Final

Infelizmente a equipa não deu continuidade ao bom momento e ficamos em último no apuramento do campeão.

Treinador do Mês:

🥇agosto

🥇dezembro

Jogador do Mês

🥇Ká - dezembro

Equipa do Ano

1a eliminatória: vs Lusitano VRSA (2-0)✅

2a eliminatória: vs Barreirense (3-2)✅

3a eliminatória: vs Arouca (2-0)✅

4a eliminatória: vs Farense (1-0)✅

5a eliminatória: vs FC Porto (0-3)❌

Fizemos uma boa campanha na taça, eliminando duas equipas da primeira liga e tendo oportunidade de jogar no dragão contra o Porto, saímos com um 0-0 ao intervalo mas depois a equipa não teve pernas😂

Melhor 11 da época

Destaques🔥

Ká: 34J - 19⚽️ - 6🅰️ - 7.06📊

Mâlik Wanya: 34J - 8⚽️ - 9🅰️ - 6.98📊

Gonçalo Batalha: 35J - 4⚽️ - 7🅰️ - 7.09📊

⭐️Recordes Batidos⭐️

Ká:

Mais golos num jogo (4 golos)

Mais golos em campeonatos (34 golos)

Mâlik Wanya - Mais Motm numa época (8)

Melhor Jogador da Época

Four years in the making... #ENG🏴󠁧󠁢󠁥󠁮󠁧󠁿VRSA🇿🇦

#RWC2023 #rugbyworldcup #semi-final

🔥unpopular opinion about food? Something you like that people hate or vice vrsa etc

LMAO so many of my opinions about food are probably unpopular 😭 like i’m so picky. but something that i like that others don’t??? hmm….. good question…..

idk this is difficult 😭 the only thing i can think of at the moment is that i know a lot of people don’t like seltzer water, but i love it???? like la croix and shit. i’ll tear it up. even just plain seltzer water, idgaf

OH wait another thing i can think of is that i used to eat ramen (like the stovetop packet ramen) with worcestershire sauce. my dad started me on that shit when i was a kid. i don’t eat ramen anymore because it’s so high in sodium LOL but i still cook with worcestershire sauce sometimes. it’s my fave

send me a “ 🔥 “ for an unpopular opinion

NEW CDM PODCAST EPISODE OUT NOW!!!

We sit down with Walter, Andrius and Josh of Connecticut sludge/prog/post-metal band VRSA. We discuss the band's journey and ever-evolving sound, the Connecticut metal scene and the balancing act that bands play between technicality, dissonance and atmosphere. We get in-depth about the growing pressure put on musicians to be both music and content creators due to the industry's new reliance on social media. We also talk about patty melts, trends in genre popularity by decade, using your phone at gigs and more.

Spotify:

YouTube:

Apple Podcasts:

Soundcloud:

VRE = Vancomycin-Resistant Enterococci. Enterocci are Gram-positive bugs that normally live in the human gut, so they don’t belong in the central nervous system (meningitis) or urinary tract (UTI). Treat with linezolid, daptomycin, tigecycline, and others.

VISA = Vancomycin-Intermediate Staphylococcus Aureus. Technically these bacteria have intermediate sensitivity to glycopeptide antibiotics, so the name should be "GISA."

VRSA = Vancomycin-Resistant Staphylococcus Aureus. Due to vanA gene. Because there have been so few cases of VISA/VRSA, there are no widespread treatment guidelines; ask your local ID specialist.

Early Learning Centre Melbourne

Located in the eastern suburbs, our centre is a community based day care service for children. The Centre is currently managed by Guardian and is open between 7.45am and 6.00pm Monday to Friday for 48 weeks of the year with closure for four weeks over Christmas vacation. Our programs are inspired by the Reggio Emilia approach to early learning and aim to match and challenge each child’s developing abilities and interests.

We offer a rich learning program that includes music, dance, cooking, art, science, language and mathematics. We focus on developing the whole child and encourage our girls to be confident, creative and well-balanced. Our teachers are experienced, dedicated and passionate about their profession and are committed to building a strong connection between home and school.

The Early Learning Centre Melbourne provides a safe and stimulating environment for children aged 3 months to six years, where they can develop not only cognitively but socially and emotionally as well. Children are able to explore their natural curiosity in the hands-on and interactive learning experiences, guided by our qualified educators. The centre is divided into age-based rooms to ensure each child receives the best quality care and learning.

All children at our Early Learning Centre will experience the benefits of a holistic, family-based curriculum influenced by the Reggio Emilia approach and the Melbourne Model. Our teachers are trained in the Emergent Curriculum, which places a significant emphasis on children learning through their interests, as they build an understanding of the world around them.

In addition to the pedagogy, our facilities, resources and outdoor spaces are designed to meet the needs of our children. We promote an inclusive, multicultural society and provide our girls with the opportunity to learn about different cultures from their peers and through experiences such as cooking, dancing, singing, gardening and exploring the outdoors.

Our Early Learning Centre Melbourne is a place where we nurture a girl’s love of learning and help her to become a lifelong learner. She will gain a solid foundation for her future, as she develops the skills she needs to thrive at school and beyond.

We are a family-owned and operated early learning centre that strives to achieve the highest standards in education, childcare and health. We are proud to have received an Outstanding rating by the Victorian Registration and Standards Authority (VRSA), as well as an A+ rating from the independent education and care sector organisation, GoodStart.

We understand that finding the right education and care services for your child can be a difficult decision. We are here to support you every step of the way. We can provide you with information about the types of education and care services available, their NQS ratings, fees and other costs, and help you compare services to find the one that suits your family’s unique needs. If you are unsure about what type of service is best for your child, we recommend booking a tour and meeting the educators to get a feel for the centre and its environment.

Our dedicated team of Academy of Early Education caring educators is committed to unlocking the full potential of every child, guiding them on a journey of exploration and discovery. With a perfect blend of structured activities and creative play, we encourage children to develop critical skills while having fun and building lasting friendships.

A Healthy Glow: the Boom in Skin Structure Infection Therapeutics

The market for treatments for skin and skin structure infections is in good health. Over the past five years, it has grown at a compound rate of over 7%, and there are signs that it will continue to grow until 2019. The major growth areas are predicted by GlobalData after an analysis of the sector.

The skin and skin structure infections (SSSI) market grew at a compound annual growth rate (CAGR) of 7.3% from $1.7 billion in 2006 to $2.4 billion in 2011, according to a GlobalData analysis. The market is expected to continue growing at a lower rate of 0.8% CAGR to $2.5 billion in 2019.

This progress can be attributed to an increase in the elderly population and a specific rise in the number of immunocompromised patients. Growth is also driven by the introduction of new antibiotics with better safety and efficacy profiles than the existing antibiotics, to which patients have developed resistance.

Five brand-name antibiotics account for the strength of the current SSSI therapeutics market: Teflaro is ceftaroline fosamil, Zyvox is linezolid, Cubicin is daptomycin, Vibativ is telavancin, Tygacil is tigecycline, and so on. Generic antibiotics like vancomycin, levofloxacin, piperacillin/tazobactam, and others are also available on the market. It is anticipated that Teflaro, a fifth-generation cephalosporin that was recently introduced in the United States, will significantly boost competition in the future.

Additionally, the efficacy and safety profiles of the currently available treatments for SSSI are favorable. However, a source of concern is the emergence of resistance as a result of the inappropriate administration of antibiotics to SSSI patients.

As a result, we welcome the anticipated approval of new medications like Tedizolid phosphate, also known as torezolid phosphate. The drug, which is expected to get approval from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) soon, has better efficacy and safety profiles than other drugs for treating SSSI, making it a promising future player.

In the global market for SSSI therapeutics, Pfizer, Theravance, Cubist, and Forest Pharmaceuticals are the top players, while Zyvox and Cubicin are the top drugs. For the next three to four years, it is anticipated that they will keep their position.

Demand and supply The SSSI therapeutics pipeline is robust, containing novel first-in-class molecules and best-in-class molecules that are currently in the late stages of clinical development. As of December 2011, 67 molecules were in various stages of clinical development in the pipeline. Five molecules make up Phase III, 16 molecules make up Phase II, and ten molecules make up Phase I. Based on their mechanism of action, the molecules can be divided into 39 first-in-class molecules, seven best-in-class molecules, and four product extensions.

The most promising molecule on the way is the tedizolid phosphate from Trius. Tedizolid was found to be effective in clinical trials in elderly patients as well as complicated and uncomplicated patients with co-morbid conditions like renal impairment and mild-to-moderate hepatic impairment. Additionally, it demonstrated superior linezolid compliance and superior safety and efficacy profiles. As a result of these factors, it is anticipated that the medication will soon be used to treat acute bacterial SSSI.

The SSSI market has a significant need that hasn't been met. Infections that are multidrug-resistant (MDR) pose a risk to patients and are associated with higher rates of morbidity and mortality than in the past. Most importantly, multi-drug resistance restricts the number of treatment options for life-threatening bacterial infections.

Vancomycin Intermediate-resistant Staphylococcus aureus (VISA) and Vancomycin-resistant Staphylococcus aureus (VRSA), two new strains of Staphylococcus aureus, have emerged, making it possible for new players to take advantage of the expanding commercial opportunities in SSSI therapeutics. Another significant clinical need in the market is drug-resistant infections acquired in hospitals. New antibiotic therapies that are effective against existing strains will frequently gain acceptance in the SSSI therapeutics market because existing strains have developed resistance to the antibiotics that are currently available.

Due to their impact on hospitalization rates and intravenous antibiotic use, SSSIs are becoming a growing source of concern for both patients and healthcare professionals. Gram-positive, Gram-negative, and anaerobic bacteria are the pathogens that cause SSSI. There are two types of bacterial skin infections. A variety of bacterial skin infections, such as cellulitis, erysipelas (superficial cellulitis), carbuncles, and impetigo, are referred to as "uncomplicated skin and skin structure infection." Staphylococcus aureus and group-A streptococci are the most prevalent uSSSI-causing organisms. Although the exact prevalence of SSSIs in the United States is unknown, the Centers for Disease Control and Prevention reports that the annual incidence of disease caused by group-A streptococcal infection is rising in workplaces, hospitals, and schools.

The most frequently treated infection in a hospital setting is a complicated skin and skin structure infection (cSSSI). Antimicrobial therapy combined with surgical intervention is the most common treatment. The clinical setting, the location of the infection, and the patient's previous medical history all influence the potential pathogens involved in cSSSIs. Resistance to pathogens has also grown.

The global SSSI therapeutics market will be driven by a growing elderly and immunocompromised population. Men and the elderly are more likely to get bacterial infections, and they are also more likely to get them in healthcare and community settings because hospital stays last longer and are more frequent. Additionally, an increase in the number of patients with suppressed immune systems has resulted in an increase in the number of patients who develop cSSSIs.

The average number of days that patients spend in the hospital has also gone up. The likelihood of getting a bacterial infection is directly proportional to the length of the visit. A patient's stay may be prolonged if the antibiotics they receive are not used appropriately. In the not-too-distant future, the increased number of patients will result in an increase in the average number of hospital stays and the cost of SSSI.

Until recently, SSSI was primarily a hospital-acquired infection; however, as the prevalence of SSSI in the community has increased, SSSI has emerged as one of the most common causes of skin infections in the United States. Multi-drug-resistant bacteria have emerged as a result of the widespread use of a small number of medications to treat SSSI, creating a significant clinical need for new antibiotics in the SSSI therapeutics market.

In the SSSI therapeutics market, there will be more generic competition as a result of drugs like Zyvox (linezolid) and Tygacil (tigecycline) expiring their patents. Pharmaceutical companies may see a low return on investment in the creation of antibiotics as a result of the widespread availability of generics. As a result, total revenue may fall. The SSSI market's total revenue will be affected by Zyvox, Tygacil, and Cubicin's patent expirations during the forecast period.

Hospitals are required to keep track of the number of patients who acquire bacterial infections while they are in the hospital and to record the cause of the infection (catheter-associated, surgical instrument-associated). Regulatory authorities impose stringent antibacterial regulations on hospitals. The rate of increase in these incidences has been the subject of numerous studies. As a result, hospitals are taking preventative measures that are lowering infection rates. The SSSI market is likely to suffer as a result of increased hospital surveillance.

In the healthcare setting, a problem exists when resistant bacterial species like MRSA, VISA, and VRSA gradually evolve. New antibiotics that are effective against these resistant species are still needed. Cubicin and Tygacil, however, are the only two novel antibiotics that have been approved thus far. Currently in development, only a small number of molecules appear to be effective against both Gram-positive and Gram-negative bacteria.

The cSSSI therapeutics market presents a significant unmet need. New players will have the chance to profit from the expanding commercial scope of the SSSI therapeutics market as a result of the evolution of VISA and VRSA. Another significant clinical need in the SSSI therapeutics market is drug-resistant infections acquired in hospitals.

New antibiotic therapies that are effective against these strains will gain frequent acceptance in the SSSI therapeutics market once they are launched because existing Gram-positive bacteria strains have developed resistance to the antibiotics that are currently available. The most significant drug-resistant pathogens that have been the focus of antibacterial R&D activity in recent years are MRSA and VRSA.

Gram-positive cocci from a patient's own skin flora are the majority of the pathogens that cause the condition. However, the Gram-negative and anaerobic bacteria that are associated with the site and source of infection are what distinguish cSSSIs. If antibiotic therapy is required, it should be started right away. Patients who exhibit signs and symptoms of cSSSI must be admitted to a hospital.

Patients are experiencing higher rates of morbidity and mortality than in the past and are at risk of contracting MDR infections. MDR restricts the therapeutic options for life-threatening, serious bacterial infections.

Antibiotics are resistant to some Gram-positive pathogens, and the rapidly expanding mycobacterium has also shown resistance. However, only daptomycin and tigecycline have been approved in the past five years to be effective against these bacteria that are resistant to antibiotics. Unmet need is also increased by MDR Gram-negative bacteria, and only one new drug has been approved in the last ten years. Pseudomonas Aeruginosa Infections Drugs Development Market, Klebsiella pneumoniae, Stenotrophomonas maltophilia, and Acinetobacter baumannii are all members of the Gram-negative bacterium. As the number of severe skin infections caused by Extended Spectrum Beta-lactamase-producing (ESBL) Gram-negative organisms rises, novel molecules capable of controlling them are required.

Serious infections, immunosuppression, neurological problems, and cardiac problems are among the side effects of taking a lot of antibiotics.

Six approved therapies, including Teflaro, which was recently approved in the United States, and numerous generic drugs make up the majority of the marketed products in the SSSI therapeutics market. The long duration of treatment for cSSSI patients drives up therapy costs. In this market, a novel molecule with superior efficacy against MDR strains of S. aureus may be able to command a premium price. Because price would be a potential point of leverage, higher levels of efficacy and safety may also be able to capture a portion of the market.

A number of market segments are likely to switch to new products that are safer and more effective. In the SSSI therapeutics market, the unmet need is significant, as demonstrated above.

Adagrasib attenuates cyclophosphamide-induced hepatotoxicity within SD rodents by reduction of oxidative stress as well as apoptosis

The emergence involving vancomycin- resilient Staphylococcus aureus (VRSA) in numerous aspects of the earth has been of great concern within medical configurations. This study had been carried out isolate pathogenic Azines. aureus via acute wounds pus taste, and also VRSA has been recognized by look at level of resistance habits using typical antibiotics and vancomycin by simply #Link# PCR. A total 54 S. aureus have been separated from trials. All S. aureus were subjected to Mike screening (towards vancomycin), Mental faculties Cardiovascular Infusion (BHI) vancomycin monitor agar check, dvd diffusion assessment.VRSA were established by PCR sound of the vanA and also vanB genetics. From this study, it absolutely was witnessed in which separated Azines. aureus ranges are pathogenic, Using the disk diffusion check, most isolates (90.3%) ended up resistant to penicillin whilst the most affordable resistance (6.9%) was to cephalothin. 3 from the 54 isolates had a vancomycin MIC associated with >Equals 128 simply by Mike testing. The 3 VRSA isolates ended up additionally extremely resistant to various other analyzed prescription medication. The present research shows the first time introduction of VRSA using this a part of Iran and also implies the actual prescription antibiotic weight within the examine place.Qualifications: Any time rhesus apes (Macaca mulatta) are employed to check malaria vaccines, animals tend to be challenged with the intravenous procedure regarding sporozoites. However, all-natural exposure to malaria comes by means of insect nip, and antibodies can easily reduce the effects of sporozoites since they navigate your skin layer. As a result, iv injection might not exactly relatively evaluate humoral immunity through anti-sporozoite malaria vaccines. To higher determine malaria vaccines inside rhesus, a method to concern more and more apes by simply mosquito chunk was made. Strategies: A number of species and also strains involving mosquitoes were tested for power to produce Plasmodium knowlesi sporozoites. Donor horse parasitaemia results upon oocyst as well as sporozoite numbers and also mosquito mortality had been noted. Methylparaben combined with bug feed ended up being analyzed to further improve insect success. To look for the quantity of gnaws had to infect a new goof, animals were encountered with numerous numbers of P. knowlesi-infected nasty flying bugs. Lastly, P. knowlesi-infected mosquitoes were chosen in order to obstacle 18 monkeys inside a malaria vaccine test, as well as the aftereffect of number of infectious gnaws on ape parasitaemia had been documented. Final results: Anopheles dirus, Anopheles crascens, as well as Anopheles dirus A (a cross between the two species) developed a lot of P. knowlesi sporozoites. Insect survival for you to morning 14, while sporozoites complete the actual salivary glands, averaged just 32% any time contributor monkeys a parasitaemia above 2%. However, whenever #Link# donor goof parasitaemia ended up being below 2%, many other insects made it two times as nicely as well as included enough sporozoites of their salivary glands. Introducing methylparaben in order to sugars remedies failed to boost survival regarding afflicted nasty flying bugs. Plasmodium knowlesi has been extremely catching, with all of #Link# monkeys developing bloodstream period microbe infections if a person or even more contaminated mosquitoes successfully fed.

Nine leftovers and outtakes from the easternmost town of the Algarve, Vila Real de Santo António.

The sentence of the second image is from the historical communist leader Álvaro Cunhal and can be translated as: “let us take in our hands the fates of our lives”. You don’t need to agree politically with the man to appreciate this sentence.

🇵🇹 Praias de #vrsa são quentes, com o mar calmo e águas cálidas e dunas em estado selvagem. . Quer saber mais sobre estas praias? Siga o nosso blog. Link na bio. . Beaches in Vila Real de Santo António in #algarve are warm, with calm seas and warm waters. They are beaches with sand dunes well preserved. . More tips in our blog. Follow the link in bio. . #prefiroviajar #travelingthroughtheworld #ilovetravel #estouaquipúblico #ilovetravelling #destinosimperdiveis #lugardeviajante #europe_vacations #weliketotravel #travelpicsdaily #traveltheworld #naturelovers #travelpicture #welivetotravel #travellingplanet #travellingourplanet #living_europe #bestplacestogo #placestosee #bestvacations #nature_photobook #featuremealgarve #voyagefascination #bestvacations #algarvefantastic #travel_algarve #featuremealgarve https://www.instagram.com/p/CEqoi7UpjpR/?igshid=uyf12liyo0tb

Heartbreak and euphoria, all in one. One Six Nations side and 3 Rugby Championship sides make it to the semi-final next week. One Six Nations side and 3 Rugby Championship sides make it to the semi-final next week.

The Southern Hemisphere teams will be playing next Friday and Saturday.

#FRA🇫🇷vRSA🇿🇦

#RWC2023 #rugbyworldcup #rugby #teams #SouthernHemisphere #semi-Final

Quick #sketch #drawing #vrsa #happy #thursday #art #artist #leo #lossantos #2019 https://www.instagram.com/p/B2mw50hg6pT/?igshid=g6zmsyrqysm2

@bigtoonz373 x @vrsa.official "CALIFORNIA" - H.A.M #HARBORAREAMOVEMENT #CALIFORNIA #BIGTOONZ #VRSA (at Harbor Area, Los Angeles, California) https://www.instagram.com/p/CdMRXe0F00G/?igshid=NGJjMDIxMWI=